Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.36 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.36 |
| ▸ | AVPR1B | P47901 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12138802 | 0.94 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9ASMN1; SMN2TGFBR1 | |
| SCHEMBL1359102 | 0.93 | AXL (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2TGFBR1 | |
| SCHEMBL1359129 | 0.89 | SMN1; SMN2 (0.46) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1360462 | 0.85 | IKBKE (0.36) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12138920 | 0.84 | SCD (0.39) | SMN1; SMN2LMNAEGFRSCD | |
| SCHEMBL12138821 | 0.83 | SMN1; SMN2 (0.42) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1359882 | 0.81 | ALDH1A1 (0.37) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12138836 | 0.80 | SMN1; SMN2 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL12138811 | 0.80 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2LMNA | |
| SCHEMBL1360623 | 0.79 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | claimed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| US-8426405-B2 | Thiazopyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2013-04-23 | — | — | US | disclosed |
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | disclosed |
| EP-2247601-B1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LTD (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2011-11-17 | — | — | US | disclosed |
| WO-2010000030-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | AVEXA LIMITED (AU) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281861-A1 | THIAZOPYRIMIDINONES AND USES THEREOF | TPMT, CYP2C19, CYP3A5 | ALDH1A1 124/4885NPC1 254/4885RAB9A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.